No trial has tested this combination in people. Each compound below has whatever evidence it has, on its own. Putting two or three of them in one vial does not combine their evidence, and no study has looked at what they do together, in what order, or at what cost. Everything on this page about the pairing is a description of what is claimed for it, not a finding.
What is in it
One of the few peptides on this list with credible controlled human data — for skin, applied topically. It occurs naturally in plasma, and its discoverer reports levels falling by more than …
- Evidence
- Moderate
- Status
- Cosmetic Ingredient
- Documented risks
- 8 · 3 serious
The smallest active piece of alpha-MSH, retaining the anti-inflammatory activity while dropping the pigmentation effects. The preclinical inflammatory bowel data is genuinely interesting. Hu…
- Evidence
- Minimal
- Status
- Research Use Only
- Documented risks
- 4 · 2 serious
Why it is sold this way
The pairing is framed as repair plus calm: GHK-Cu for collagen synthesis and skin remodelling, KPV for its anti-inflammatory action. Both are small, both are stable enough to formulate, and the combination is sold both topically and, less defensibly, for injection.
What the combination actually has behind it
GHK-Cu has real human evidence, and it is topical and cosmetic. KPV has essentially none in humans. The combination has never been tested. There is also a specific chemical question that the marketing does not raise: GHK-Cu is a copper complex, and its activity depends on that copper being where it should be — putting it in a vial with another peptide and whatever excipients are present is a formulation problem, not a neutral act.
| GHK-Cu |
3/5 Moderate
Evidence rating 3 out of 5: Moderate
Small or early-phase human trials, or good controlled topical human data. |
|---|---|
| KPV |
1/5 Minimal
Evidence rating 1 out of 5: Minimal
Animal or laboratory data only. No human efficacy evidence. |
| The blend | No human trial of the combination exists. The figure that matters for a mixture is its weakest component, which here is 1 of 5. |
What mixing them makes impossible
The route confusion in this category is the main hazard. Evidence generated for a cream applied to the face does not transfer to an injection, and the GHK-Cu monograph says so explicitly. A blend sold for both uses invites exactly that transfer.
Change one thing at a time. This is the most useful rule on the safety page and a fixed mixture breaks it by design. If a blend helps, you cannot say which part helped; if it harms, you cannot say which part harmed, or stop that part alone.
Regulatory status
Topical GHK-Cu is a lawful cosmetic ingredient and that is where its human evidence comes from. The compounding position of each component, which is a separate question and has moved more than once, is in the dated record below.
| GHK-Cu | Off Category 2, not authorised Off Category 2 since April 2026 with no committee vote yet: neither prohibited as a significant safety risk nor authorised for compounding. |
|---|---|
| KPV | Advisory committee recommended Off Category 2 since April 2026 and recommended by the FDA’s advisory committee in July 2026 — but not yet on the 503A bulks list, so not yet lawfully compoundable. |
The dated record for the compounds this site tracks is on the compounding status page, which is checked against the FDA's own documents rather than against anybody's description of them. A committee recommendation is not FDA action, removal from a list is not permission, and none of it is drug approval.
Related compounds
This page is educational information, not medical advice. It cannot account for your medical history, medications or risk factors. Do not start, stop or change any treatment based on it.